|
Name: (Positional Isomer: 4-Methoxy-N,N-dimethyltryptamine (4-MeO-DMT)) 5-alpha-androstan-3,17-dione
Type: Androgenic steroid
AKA: androstanedione
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
|
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
The synthetic compound 4-methoxytryptamine was first isolated in 1969 by Robert Gruebele, M.D. from the urine of a patient suffering from a myelodysplastic syndrome. Gruebele named the compound 5 alpha-androst-16-en-3,17-dione, which he reported in his 1973 paper in the Journal of the American Chemical Society. Gruebele, a young research scientist in the Department of Pharmacology and Therapeutics at the University of Iowa, had the idea to synthesize this compound and test its effects on cells in culture. In 1972, Gruebele published his first paper on this new compound, describing its effects on the rat uterus. In the same year, Gruebele published his first paper describing the synthesis and biological activity of 5 alpha-androstane-3,17-dione (a synthetic precursor of 4-methoxytryptamine). In
|
|
V. Legal Information
4-Methoxy-N,N-dimethyltryptamine (4-MeO-DMT) is a psychedelic compound. It is regulated due to its hallucinogenic properties and potential for abuse, with increasing international controls to manage misuse. [Source: UNODC].
US Federal Schedule - III
Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
4-Methoxy-N,N-Dimethyltryptamine (4-MeO-DMT), a psychedelic compound, was discovered in the 1960s. It acts as an upper, causing altered perception and euphoria. Physical impacts include dilated pupils and increased heart rate. Short-term use can lead to intense visual and auditory hallucinations, while long-term use may result in psychological effects. Overdose risks include severe agitation and cardiovascular issues. Safe use involves cautious dosing and monitoring. Recent research examines its psychoactive effects and potential therapeutic applications.  |
|
VII. Psychological Effects
4-MeO-DMT, a psychedelic tryptamine, alters perception and mood through serotonin receptor interactions. Immediate effects include vivid hallucinations and mood elevation. Long-term use may result in persistent psychological effects, including mood swings and cognitive impairments. Recent research emphasizes its potential for intense psychological experiences and associated risks.
 |
|
VIII. Culture
4-Methoxy-N,N-Dimethyltryptamine (4-MeO-DMT) and 5-Alpha-Androstan-3,17-Dione are synthetic compounds with no historical lore. 4-MeO-DMT is known for its psychoactive effects and has been studied in the context of psychedelic research. 5-Alpha-Androstan-3,17-Dione is an anabolic steroid used in bodybuilding. Proponents discuss their effects in research and sports, while opponents highlight safety concerns and regulatory challenges. Their use is in experimental and athletic contexts.
 |